CMPS COMPASS Pathways PLC Future Profit

COMPASS Pathways plc (CMPS) - corporate logo

COMPASS Pathways plc (CMPS) holds a patent for synthetic psilocybin, which promises the company pricing power. A strong talent pool is driven by its mission to rescue mental health. However, the company is currently only developing commercial reimbursement schemes. The trend of prospective revenues demonstrates the business development vector, where the level captures the current state of expected profits.

COMPASS Pathways plc (CMPS): Forward Earnings from 07/04/2022 to 11/10/2026

Metric breakdowns and analytics for COMPASS Pathways PLC (CMPS)

- share price and consensus valuation forecast:
Stock Price COMPASS Pathways plc|CMPS - Analyst Consensus Forecast
- market capitalization data:
Market Valuation COMPASS Pathways|CMPS - Value Adjusted for Debt and Cash
- book capitalization information:
Net Assets per Single Share COMPASS Pathways|CMPS - Net Asset Value|Market Value to Book Value Ratio compasspathways.com|CMPS - Company Total Asset Base
- company total debt and liquidity indicators:
Total Debt to Equity Ratio COMPASS Pathways plc|CMPS - Long-Term Liabilities to Capital|Short-Term Debt to Capital Compass Pathways|CMPS - Company Total Debt|Debts to Book Capitalization COMPASS Pathways|CMPS - Company Long-Term Loans and Borrowings|Company Short-Term Debt COMPASS Pathways|Quick Ratio compasspathways.com
- net income and valuation ratios data:
CMPS - Net Income|Expected Profit COMPASS Pathways plc|CMPS - Market Cap to Earnings|Future Price to Earnings COMPASS Pathways|CMPS - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization COMPASS Pathways|CMPS - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) COMPASS Pathways|CMPS - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months compasspathways.com|CMPS - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year COMPASS Pathways plc
Comprehensive company analysis:COMPASS Pathways plc, CMPS
Brand item of COMPASS Pathways PLC

This indicator reflects the consensus forecast for the issuer's future earnings, allowing for an assessment of the risk of overpaying for the asset when an illusion of infinite return on capital growth arises. Analyzing the projected profit level helps avoid freezing funds, particularly for COMPASS Pathways plc (CMPS), where colossal unmet demand for depression therapy creates a fundamental basis for scaling future cash flows.

Competitor analysis for COMPASS Pathways plc

ALKS (Alkermes plc) - Projected Future Earnings|Projected Future Earnings avadel.com|Future Profit ATAI (atai Life Sciences)|GHRS (GH Research plc) - Expected Net Income|Expected Profit MindMed Inc. MNMD|LBRX (LB Corp) - Forward Earnings|DRUG - Expected Profit|Company Profit Forecast vandapharma.com VNDA|CYBN (cybin.com) - Future Profit|Expected Net Profit Alto Neuroscience Inc (ANRO)|NRXP (NRx Pharma) - Projected Future Earnings|Future Profit Cingulate Corp (CING)|Projected Future Earnings SILO|CPHI (chinapharmaholdings.com) - Expected Net Income|Expected Profit Clearmind Medicine Inc. CMND|Psyence Biomedical Ltd (PBM) - Expected Net Profit|Clearmind Medicine - Projected Future Earnings|Seelos Therapeutics Inc (SEEL) - Future Profit|virpaxpharma.com (VRPX) - Expected Profit|Expected Net Profit karunatx.com (KRTX)